Published in Health Psychol on January 01, 2009
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Strategies for reducing regional variation in the use of surgery: a systematic review. Ann Surg (2014) 1.63
Intervention taxonomy (ITAX): describing essential features of interventions. Am J Health Behav (2010) 1.46
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
Clinical decision support for genetically guided personalized medicine: a systematic review. J Am Med Inform Assoc (2012) 1.26
Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2010) 1.19
Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev (2012) 1.08
Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial. Med Decis Making (2010) 1.03
The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information. J Pers Med (2013) 0.97
Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results. Health Psychol (2009) 0.95
Long-term reactions to genetic testing for BRCA1 and BRCA2 mutations: does time heal women's concerns? J Clin Oncol (2011) 0.94
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Res Treat (2010) 0.92
BRCA1/2 genetic testing uptake and psychosocial outcomes in men. Fam Cancer (2011) 0.91
Features of Computer-Based Decision Aids: Systematic Review, Thematic Synthesis, and Meta-Analyses. J Med Internet Res (2016) 0.84
Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns (2011) 0.82
Estimating and disclosing the risk of developing Alzheimer's disease: challenges, controversies and future directions. Future Neurol (2010) 0.81
Are cancer-related decision aids appropriate for socially disadvantaged patients? A systematic review of US randomized controlled trials. BMC Med Inform Decis Mak (2016) 0.81
Impact of web-based case conferencing on cancer genetics training outcomes for community-based clinicians. J Cancer Educ (2012) 0.80
Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers. Hered Cancer Clin Pract (2014) 0.80
Seeking balance: decision support needs of women without cancer and a deleterious BRCA1 or BRCA2 mutation. J Genet Couns (2013) 0.79
Bridging the Communication Divide: A Role for Health Psychology in the Genomic Era. Prof Psychol Res Pr (2012) 0.78
Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling. Psychooncology (2014) 0.77
Decision making for breast cancer prevention among women at elevated risk. Breast Cancer Res (2017) 0.75
The Many Facets of Genetic Literacy: Assessing the Scalability of Multiple Measures for Broad Use in Survey Research. PLoS One (2015) 0.75
Feasibility evaluation of an online tool to guide decisions for BRCA1/2 mutation carriers. Fam Cancer (2013) 0.75
Understanding the Needs of Young Women Regarding Breast Cancer Risk Assessment and Genetic Testing: Convergence and Divergence among Patient-Counselor Perceptions and the Promise of Peer Support. Healthcare (Basel) (2016) 0.75
It's the amount of thought that counts: when ambivalence contributes to mammography screening delay. Womens Health Issues (2011) 0.75
Engagement and communication among participants in the ClinSeq Genomic Sequencing Study. Genet Med (2016) 0.75
Improving Decision Making about Genetic Testing in the Clinic: An Overview of Effective Knowledge Translation Interventions. PLoS One (2016) 0.75
Validation of a decisional conflict scale. Med Decis Making (1995) 12.19
Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev (2003) 10.43
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns (1998) 5.40
Effect of a decision aid on knowledge and treatment decision making for breast cancer surgery: a randomized trial. JAMA (2004) 4.18
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Patient satisfaction with health care decisions: the satisfaction with decision scale. Med Decis Making (1996) 3.85
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol (2005) 2.51
Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet A (2003) 2.29
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol (2002) 2.13
Decision aids and breast cancer: do they influence choice for surgery and knowledge of treatment options? J Clin Oncol (2007) 2.09
An evidence-based approach to managing women's decisional conflict. J Obstet Gynecol Neonatal Nurs (2002) 1.77
Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med (2004) 1.70
Randomized trial of a patient decision aid for choice of surgical treatment for breast cancer. Med Decis Making (2001) 1.68
Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol (2001) 1.63
A community-based randomised controlled trial of three different educational resources for men about prostate cancer screening. Patient Educ Couns (2005) 1.53
Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg (2000) 1.50
Decision support for patients with early-stage breast cancer: effects of an interactive breast cancer CDROM on treatment decision, satisfaction, and quality of life. J Clin Oncol (2001) 1.36
Randomized trial of a shared decision-making intervention consisting of trade-offs and individualized treatment information for BRCA1/2 mutation carriers. J Clin Oncol (2004) 1.25
Impact of educational print materials on knowledge, attitudes, and interest in BRCA1/BRCA2: testing among Ashkenazi Jewish women. Cancer (2001) 1.24
Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin Genet (2007) 1.21
A BRCA1/2 mutation, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography. Int J Cancer (2002) 1.14
Decision making and decision support for hereditary breast-ovarian cancer susceptibility. Health Psychol (2005) 1.05
Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. Br J Cancer (2004) 1.04
Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev (2002) 0.99
A randomized controlled trial of a decision aid for women considering genetic testing for breast and ovarian cancer risk. Breast Cancer Res Treat (2007) 0.97
Development of an Interactive Decision Aid for Female BRCA1/BRCA2 Carriers. J Genet Couns (2003) 0.96
Update on hereditary breast cancer. Curr Oncol Rep (2006) 0.89
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol (2009) 3.59
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Clinically relevant changes in family history of cancer over time. JAMA (2011) 3.18
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. Thorax (2007) 2.86
Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet (2003) 2.81
Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J Natl Cancer Inst (2008) 2.78
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol (2009) 2.52
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
The Group-Based Medical Mistrust Scale: psychometric properties and association with breast cancer screening. Prev Med (2004) 2.48
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol (2005) 2.42
Hot flushes. Lancet (2002) 2.28
How do perceptions of local neighborhood relate to adolescents' walking and cycling? Am J Health Promot (2005) 2.18
Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study. Radiology (2007) 2.18
Impact of BRCA1/BRCA2 mutation testing on psychologic distress in a clinic-based sample. J Clin Oncol (2002) 2.13
Interactions between genetic variants and breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer Inst (2011) 2.09
Characterization of long-term outcomes after Toupet fundoplication: symptoms, medication use, and health status. J Clin Gastroenterol (2002) 2.08
Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. J Natl Cancer Inst (2004) 2.06
All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet (2002) 2.05
Perceived disadvantages and concerns about abuses of genetic testing for cancer risk: differences across African American, Latina and Caucasian women. Patient Educ Couns (2003) 2.03
Reversible coma in children after improper baclofen pump insertion. Paediatr Anaesth (2002) 2.02
Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev (2011) 1.99
Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med (2007) 1.94
Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors. J Genet Couns (2011) 1.92
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res (2010) 1.90
Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res (2010) 1.89
Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest (2011) 1.89
Awareness of genetic testing for colorectal cancer predisposition among specialists in gastroenterology. Am J Gastroenterol (2002) 1.86
Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res (2010) 1.82
Tumor suppressor BRCA1 epigenetically controls oncogenic microRNA-155. Nat Med (2011) 1.79
Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol (2006) 1.79
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma (2010) 1.78
Resveratrol in human cancer chemoprevention--choosing the 'right' dose. Mol Nutr Food Res (2011) 1.77
Effect of preventive messages tailored to family history on health behaviors: the Family Healthware Impact Trial. Ann Fam Med (2011) 1.75
Benefits and costs of interventions to improve breast cancer outcomes in African American women. J Clin Oncol (2004) 1.75
AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev (2007) 1.75
What is new for an old molecule? Systematic review and recommendations on the use of resveratrol. PLoS One (2011) 1.74
The demographics and distribution of type B Niemann-Pick disease: novel mutations lead to new genotype/phenotype correlations. Am J Hum Genet (2002) 1.74
Take note(s): differential EHR satisfaction with two implementations under one roof. J Am Med Inform Assoc (2003) 1.73
A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. Health Psychol (2002) 1.69
Psychosocial predictors of BRCA counseling and testing decisions among urban African-American women. Cancer Epidemiol Biomarkers Prev (2002) 1.68
Clinical trials of resveratrol. Ann N Y Acad Sci (2011) 1.66
Measuring patient-centered communication in cancer care: a literature review and the development of a systematic approach. Soc Sci Med (2011) 1.63
Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care (2009) 1.62
The Cancer Genetics Network: recruitment results and pilot studies. Community Genet (2003) 1.61
Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol (2005) 1.58
Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med (2014) 1.57
Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol (2008) 1.57
Clinician perspectives about molecular genetic testing for heritable conditions and development of a clinician-friendly laboratory report. J Mol Diagn (2009) 1.54
Coffee consumption and breast cancer risk among BRCA1 and BRCA2 mutation carriers. Int J Cancer (2006) 1.53
Estrogen metabolism and risk of breast cancer in postmenopausal women. J Natl Cancer Inst (2012) 1.53
The SPECTRUM population model of the impact of screening and treatment on U.S. breast cancer trends from 1975 to 2000: principles and practice of the model methods. J Natl Cancer Inst Monogr (2006) 1.52
The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat (2006) 1.51
Pilot study of oral anthocyanins for colorectal cancer chemoprevention. Cancer Prev Res (Phila) (2009) 1.50
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer (2005) 1.48
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns (2002) 1.47
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
Experiences of racist events are associated with negative health consequences for African American women. J Natl Med Assoc (2003) 1.44
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer. Clin Cancer Res (2003) 1.43
Is outcomes research on cancer ready for prime time? Med Care (2002) 1.41
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol (2006) 1.41
Correspondence regarding M. Sharma et al., "Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture". Biochem Biophys Res Commun (2003) 1.41
Demographic, medical, and psychosocial correlates to CAM use among survivors of colorectal cancer. Support Care Cancer (2007) 1.40
Ordering molecular genetic tests and reporting results: practices in laboratory and clinical settings. J Mol Diagn (2008) 1.40
Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver. Hum Gene Ther (2006) 1.39
Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol (2003) 1.38